Guidelines of the Polish Society of Pediatric Endocrinology and Diabetology and Pediatric Section of Diabetes Poland on Insulin Therapy Using Hybrid Closed-loop Systems in Children and Adolescents with Diabetes in Poland

Overview

Journal Pediatr Endocrinol Diabetes Metab

Publisher Termedia

Specialty Pediatrics

Date 2024 Oct 25

PMID 39451186

Authors

Agnieszka Szadkowska

Agata Chobot

Barbara Glowinska-Olszewska

Przemyslawa Jarosz-Chobot

Beata Mianowska

Malgorzata Mysliwiec

Agnieszka Szypowska

Agnieszka Zubkiewicz-Kucharska

Mieczyslaw Walczak

Affiliations

Soon will be listed here.

Abstract

Currently, hybrid closed loop (HCL) systems represent the most advantageous therapeutic option for people with diabetes requiring intensive insulin therapy. They make it possible to achieve optimal metabolic control of the disease in any age group while improving the quality of life of children and adolescents with diabetes and their families. Therefore, we present recommendations for the use of HCL systems in children and adolescents focusing on systems currently available in Poland. These systems should be the first choice in terms of method of insulin therapy in the paediatric population. They can be implemented at any stage of diabetes management. These recommendations are based on scientific evidence and experts' experience. They include principles for the initiation, optimisation, and ongoing management of HCL therapy, as well as the required HCL-related education.

References

Jendle J, Buompensiere M, Ozdemir Saltik A, de Portu S, Smith-Palmer J, Pollock R . A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes. Diabetes Technol Ther. 2023; 25(12):864-876. DOI: 10.1089/dia.2023.0297. View

Petrovski G, Al Khalaf F, Campbell J, Day E, Almajaly D, Hussain K . Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI). BMC Endocr Disord. 2022; 22(1):80. PMC: 8962027. DOI: 10.1186/s12902-022-00996-7. View

Luijf Y, van Bon A, Hoekstra J, DeVries J . Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010; 33(10):2152-5. PMC: 2945151. DOI: 10.2337/dc10-0692. View

Nefs G . The Psychological Implications of Automated Insulin Delivery Systems in Type 1 Diabetes Care. Front Clin Diabetes Healthc. 2023; 3:846162. PMC: 10012062. DOI: 10.3389/fcdhc.2022.846162. View

Castaneda J, Mathieu C, Aanstoot H, Arrieta A, Da Silva J, Shin J . Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes Metab. 2022; 24(11):2212-2221. DOI: 10.1111/dom.14807. View

Abraham M, de Bock M, Smith G, Dart J, Fairchild J, King B . Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA Pediatr. 2021; 175(12):1227-1235. PMC: 8506294. DOI: 10.1001/jamapediatrics.2021.3965. View

Seget S, Jarosz-Chobot P, Ochab A, Polanska J, Rusak E, Witoszek P . Body mass index, basal insulin and glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system remain stable - 1-year prospective, observational, two-center study. Front Endocrinol (Lausanne). 2022; 13:1036808. PMC: 9592809. DOI: 10.3389/fendo.2022.1036808. View

Adolfsson P, Hanas R, Zaharieva D, Dovc K, Jendle J . Automated Insulin Delivery Systems in Pediatric Type 1 Diabetes: A Narrative Review. J Diabetes Sci Technol. 2024; 18(6):1324-1333. PMC: 11535396. DOI: 10.1177/19322968241248404. View

Sherr J, Schoelwer M, Dos Santos T, Reddy L, Biester T, Galderisi A . ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatr Diabetes. 2022; 23(8):1406-1431. DOI: 10.1111/pedi.13421. View

10.

Tauschmann M, Forlenza G, Hood K, Cardona-Hernandez R, Giani E, Hendrieckx C . ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes. 2022; 23(8):1390-1405. PMC: 10107687. DOI: 10.1111/pedi.13451. View

11.

Schiaffini R, Lumaca A, Martino M, Rapini N, Deodati A, Amodeo M . Time In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologies. Diabetes Metab Res Rev. 2024; 40(5):e3826. DOI: 10.1002/dmrr.3826. View

12.

Matejko B, Van den Heuvel T, Castaneda J, Arrieta A, Cyranka K, Cohen O . Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort. Diabetes Res Clin Pract. 2024; 216:111832. DOI: 10.1016/j.diabres.2024.111832. View

13.

Berget C, Messer L, Forlenza G . A Clinical Overview of Insulin Pump Therapy for the Management of Diabetes: Past, Present, and Future of Intensive Therapy. Diabetes Spectr. 2019; 32(3):194-204. PMC: 6695255. DOI: 10.2337/ds18-0091. View

14.

Choudhary P, Arrieta A, Van den Heuvel T, Castaneda J, Smaniotto V, Cohen O . Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence. Diabetes Technol Ther. 2024; 26(S3):32-37. PMC: 10890936. DOI: 10.1089/dia.2023.0433. View

15.

Mianowska B, Fendler W, Tomasik B, Mlynarski W, Szadkowska A . Effect of Insulin Dilution on Lowering Glycemic Variability in Pump-Treated Young Children with Inadequately Controlled Type 1 Diabetes. Diabetes Technol Ther. 2015; 17(9):605-10. DOI: 10.1089/dia.2014.0392. View

16.

Phillip M, Nimri R, Bergenstal R, Barnard-Kelly K, Danne T, Hovorka R . Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2022; 44(2):254-280. PMC: 9985411. DOI: 10.1210/endrev/bnac022. View

17.

Boughton C, Hartnell S, Allen J, Fuchs J, Hovorka R . Training and Support for Hybrid Closed-Loop Therapy. J Diabetes Sci Technol. 2020; 16(1):218-223. PMC: 8739578. DOI: 10.1177/1932296820955168. View

18.

Mathieu C, Ahmed W, Gillard P, Cohen O, Vigersky R, de Portu S . The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review. Diabetes Technol Ther. 2024; 26(S3):66-75. DOI: 10.1089/dia.2023.0438. View

19.

Benhalima K, Beunen K, Van Wilder N, Ballaux D, Vanhaverbeke G, Taes Y . Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2024; 12(6):390-403. DOI: 10.1016/S2213-8587(24)00089-5. View

20.

Piccini B, Felicioni M, Pessina B, Bertini M, Casalini E, Ceccotti C . Glycemic Control, Basal/Bolus Distribution, BMI and Meal Management in Children and Adolescents with Type 1 Diabetes and Advanced Hybrid Closed Loop. Nutrients. 2023; 15(23). PMC: 10707798. DOI: 10.3390/nu15234875. View